Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2020 Aug 26;19(10):2057–2067. doi: 10.1158/1535-7163.MCT-20-0134

Figure 6: Impact of pre-existing measles neutralizing antibodies on the oncolytic activity of EGFR-retargeted viruses.

Figure 6:

MVCDVenvEGFR maintained oncolytic efficacy in the presence of pre-existing anti-measles neutralizing antibodies. A) schematic of experimental design. Athymic mice with i.p. SKOV3ip.1Fluc tumors were treated with a single i.p. injection of 2 × 106 TCID50 of MVEGFR, MVCDVenvEGFR or 200 μL control (producer vero-⍺His lysate), with or without 200 μL (60 EU) of pooled human measles-immune neutralizing serum added 3 hours before virus treatment (n=10 mice/group). Representative (5 animals/ group) images (B) quantification (C) of serial bioluminescent imaging and (D) overall survival of treated animals *p<0.05; *** P<0.0001.